Menu

Mike

Meet Temi, the Personal Robot You Never Knew You Needed (But Totally Do)

Leave a Comment / Robotemi / By

What is your professional background? How did you end up in this space?
I have always been a techie. I’ve been fixing and building computers since I can remember. In my professional life, I utilized the technological advances in filmmaking and built a guerilla-specialized film production company. I was first introduced to “temi” then, and after a few collaborations with the company, the founder and CEO saw potential in me and my responsibilities grew until I became the CEO of the U.S. company.

Roboteam announces AI-CU software

Leave a Comment / Roboteam / By

On 1 March Roboteam announced the launch of its Artificial Intelligence Control Unit (AI-CU) software to provide autonomous and artificial intelligence capabilities to the warfighters. The AI-CU software will provide intuitive control and operation of unmanned systems and payloads according to the company. This will include unique features such as autonomous navigation, facial recognition and other artificial intelligence-enabled capabilities for operators of unmanned systems.

Mapi Pharma to Present Phase II Extension Results of Glatiramer Acetate Depot (GA Depot) at the 2019 AAN Annual Meeting in Philadelphia on May 7 2019

Leave a Comment / Posts / By

NESS ZIONA, Israel – April 30, 2019 – Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company will present two year clinical data from its Phase II study of GA Depot for the treatment of relapsing remitting multiple sclerosis (RRMS), at the American Academy of Neurology (AAN) Annual Meeting that will take place May 4-10, 2019. Mapi Pharma’s poster titled “Glatiramer Acetate Depot (Extended-Release) Phase II Study in Patients with Relapsing Remitting Multiple Sclerosis: Safety, Tolerability and Efficacy (No Evidence of Disease Activity) Two-Years Analysis” will be presented on May 7 between 5:30-6:30 pm EDT as Poster Number 2-052 | Poster Session P3 | Poster Neighborhood 2.

Mapi Pharma Receives Government of Israel Funding for the Establishment of a Finished Dosage Form Facility for the Manufacturing of GA Depot Pharmaceuticals

Leave a Comment / Mapi Pharma / By

NESS ZIONA, Israel – March 18, 2019 – Mapi Pharma Ltd., a fully integrated, clinical, late stagebiopharmaceutical company, announced today that it has received complementary funding fromthe Israeli Ministry of the Economy to build a new sterile production plant for GA Depot injectableproducts. The approved financing plan is for a pioneering production plant for the manufacturingof a slow release formulation of Glatiramer Acetate (GA) (Copaxone®) for treating multiplesclerosis. The plant will be built in Jerusalem, a Zone A region, allowing tax and grants benefits, inan investment of over 46 million NIS, of which the grant is set at over 9 million NIS. The plant willlead to the hiring of an additional 30 employees and all sales are expected to be exported.

TRIA Orthopedics First in Minnesota to Test Breakthrough GelrinC™ Implant to Regenerate Knee Cartilage

Leave a Comment / Regentis / By

MINNEAPOLIS, Minn. – Nov. 27, 2018 – Regentis Biomaterials today announced that Twin Cities-based
TRIA Orthopedics is the first in Minnesota to perform a procedure using the GelrinC™ implant to treat
damaged articular cartilage causing knee pain. GelrinC (pronounce “gel-rin-cee”) is an investigational
device being evaluated as a treatment to help the body regrow cartilage in the knee. TRIA is the only site
in Minnesota – and just one of 17 sites nationwide – enrolling patients with knee pain caused by
damaged knee cartilage in the SAGE clinical trial.

Stem Cell Medicine (SCM) Receives Israeli Government Funding for Gene Therapy Facility

Leave a Comment / Stemcell / By

Production Facility to be built in JerusalemJERUSALEM Israel, March 26, 2019 — Stem Cell Medicine Ltd. (SCM), a biotechnology company developing new therapies for neurological indications and rare diseases through gene therapy, cell therapy, exosomes, novel molecules and combinations with existing pharmaceuticals, announced today that it has received funding from the Israeli Ministry of the Economy to build a gene therapy facility. The new facility will enable SCM to manufacture gene therapy products for commercial launches, benefiting from the favorable global regulatory and marketing environment for its products. The first gene therapy product under development at SCM is for the treatment of neuropathic pain.

Contact us

Contact us for any questions and we will get back to you as soon as possible

2019 Crossroad Fund | BIT Enterprises Ltd.